Wilex, Telix deal

Wilex granted newco Telix exclusive, worldwide rights to develop and commercialize Redectane (124-iodine-girentuximab). The radiolabeled WX-G250 antibody has completed one Phase III trial as a diagnostic imaging agent for clear cell renal cell carcinoma (RCC). Telix is responsible for all development and commercialization costs. Wilex is eligible to receive up to $3.7 million in an upfront payment and milestones, plus royalties. ...